Objective Maternal plasma is a source of circulating placental nucleic acids. This study was designed to detect aberrantly expressed placental mRNA genes circulating in the maternal plasma of pregnancies affected with fetal conotruncal anomalies (CNTRA) and left-ventricular outflow tract (LVOT) obstruction in the second trimester of pregnancy. Methods This was a retrospective monocentric study conducted from 1 Jan 2016 to 31 Dec 2016. NanoString technology was used to identify aberrantly expressed genes, comparing 36 women carrying a fetus with CNTRA or LVOT obstruction to 42 controls at 19-24 weeks of gestation. The genes with differential expression were subsequently tested using real-time polymerase chain reaction. Linear discriminant analysis was used to combine all the mRNA species with discriminant ability for CNTRA and LVOT obstruction. A multivariable receiver operating characteristic (ROC) curve having the estimated discriminant score as an explanatory variable was generated for the two affected groups versus controls. Results Three genes with differential expression, namely MAPK1, IQGAP1 and Visfatin were found. The ROC curves yielded detection rates of 60 and 62.5% at a falsepositive rate of 5% for CNTRA and LVOT, respectively. Conclusions These data suggested that molecular screening of CNTRA and LVOT obstruction in the second trimester is feasible. Prospective studies are needed to test the discriminant ability of these genes and to calculate the predictive positive value in the general population.
Introduction
Congenital heart defects (CHDs) are complex groups of malformations. It is estimated that 4-10 liveborn infants per 1000 have a cardiac malformation, 40% of which are
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diagnosed in the first year of life [1, 2] . Approximately half of the cases of CHDs are severe, and surgery is usually required in the neonatal period or during childhood [3] . Risk factors for CHDs are maternal diabetes, use of teratogenic drugs and genetic factors, most of which are still unexplored [4] . Approximately 30% of patients with syndromic CHDs are affected with chromosomal anomalies, Mendelian syndromes and non-Mendelian associations, whereas the majority of non-syndromic CHDs probably follow a multifactorial model of inheritance [5] . Some genetic diseases are preferentially associated with specific CHDs, such as atrioventricular septal defects in Down syndrome or aortic coarctation in Turner syndrome [6] . Among the sub-microscopic anomalies, the 22q.11.2 and 7q11.23 microdeletions (DiGeorge and Williams syndrome, respectively) also have common malformative patterns, mainly conotruncal malformation, an example of an associated malformation with DiGeorge syndrome is supravalvular aortic and pulmonary stenosis [7] . More interestingly, microduplications of the same microregions (22q.11.2 and 7q11.23) have also been associated with CHDs, including septal defects, conotruncal anomalies (CNTRA) and left-ventricular outflow tract (LVOT) obstruction for 22q.11.2, and patent ductus arteriosus and aortopathy for 7q11.23 [6, 8] . There are many other examples of microdeletions and duplications associated with CHDs, such as the 1q21.1 deletion, which has been associated with LVOT obstruction, septal defects and CNTRA, as reviewed by Digilio et al. [9] , also the 8p23.1 deletion [10] , and the terminal 4p deletion [11] .
The CNTRA include tetralogy of Fallot (TOF), complete transposition of the great arteries (TGA), double outlet right ventricle (DORV) and truncus arteriosus [12] .
The four anatomical features of TOF are ventricular septal defect, overriding aorta, sub-pulmonary stenosis and right-ventricular hypertrophy. Not all these anomalies are visible before birth [13] . The TOF condition can be mild if the pulmonary arteries are well developed, or severe with narrow pulmonary arteries and consequent neonatal cyanosis [13] .
Complete TGA is a condition in which there is a discordant ventriculoarterial connection, with the aorta arising from the right ventricle and the pulmonary artery from the left ventricle [14] . This is a ductal-dependent condition, in which neonatal survival depends entirely on fetal shunts; prostaglandin E1 infusion is therefore mandatory at birth. It should be noted that the four-chamber view is normal in TGA [14] .
A DORV is a heterogenic condition involving different clinical entities in which both great vessels arise from the right ventricle [15] . A ventricular septal defect (VSD) is always present, but may be sub-aortic, sub-pulmonary, doubly committed, or not committed, according to its location [15] . The consequences of this condition at birth are determined by the type of VSD, for example, a DORV with sub-aortic VSDs is very similar to TOF, whereas a DORV with sub-pulmonary VSD is similar to TGA [15] .
Truncus arteriosus is a condition in which only one arterial vessel, with a single valve, arises from the base of the ventricles and then branches into the aorta and the pulmonary arteries [16] . Different types of truncus arteriosus have been described, according to the different origins of the systemic, coronary and pulmonary vessels from the common trunk; a VSD is often present immediately underneath the common arterial valve [16] .
LVOT obstructions include aortic arch coarctation or interruption, aortic stenosis and hypoplastic left heart syndrome (HLHS).
Aortic coarctation is commonly suspected in the third trimester of pregnancy when indirect signs of left obstruction are detectable (right-left disproportion with prevalence of the right ventricle and pulmonary artery) or direct visualization of an abnormal morphology of the arch (aortic shelf) [17] . Prenatal diagnosis of this condition is difficult, not only because it can easily be missed, but also because indirect signs often lead to a false diagnosis [17] . When identified, aortic coarctation can be completely corrected after birth with a good prognosis.
Aortic arch interruption type B is a similar condition, in which a prenatal diagnosis is more frequent. It is rarely isolated and is more often associated with genetic syndromes (mainly, Di George syndrome) [18] .
Aortic stenosis may have different aspects according to the degree of obstruction. If the obstruction is moderate to severe, the left ventricle will appear normal or mildly hypertrophic, but if the stenosis is critical, the left ventricle will appear dilated and poorly contracted, with signs of fibro-elastosis [19] . The degree of aortic stenosis may be progressive in pregnancy [19] .
Finally, aortic atresia, leading to HLHS, is a very severe obstructive lesion in which the left part of the heart fails to develop properly during pregnancy [20] . This condition is easy to detect even at an early gestational age and usually has a poor fetal prognosis because a biventricular correction is not guaranteed.
If not detected antenatally, all LVOT obstructions are potentially dangerous conditions, often causing neonatal death because closure of fetal shunts at birth prevents normal distribution of the blood to the descending aorta.
Ultrasound detection of CHDs is not always easy, especially at a routine anomaly scan, if dedicated fetal echocardiography is not performed. Therefore, a non-invasive screening tool, based for example on circulating nucleic acids in maternal plasma like the mRNAs, would be particularly useful to increase ultrasound surveillance in cases that screened positive. As opposed to circulating fetal DNA, the mRNA dosage in maternal plasma has, so far, been poorly investigated. Fetal DNA is efficient for screening genetic syndromes such as Down and other trisomies but mRNA could be more useful in those conditions of abnormal fetal morphogenesis and of a temporaneous or permanent aberration of some fetal and placental transcripts. This is supported by previous studies that have demonstrated that aberrant placental mRNA and micro RNA (miRNA) species related to cardiogenesis and cardiac failure can be detected in maternal plasma in the second trimester of pregnancy [21] [22] [23] .
The aim of the present study was to (1) present NanoString technology as a possible tool for mRNAs dosage (2) to compare the mRNA expression of aberrantly expressed genes in mothers carrying a fetus with CNTRA or LVOT obstruction as compared to controls, and (3) to analyse the performance of this potential molecular screening tool.
Material and Methods
The study was a monocentric retrospective evaluation of major CHDs referred to our Division of Fetal Medicine, matched for gestational age with controls. Fetuses having known chromosomal anomalies and multiple extra-cardiac congenital anomalies were excluded. The study was carried out according to the ethical rules of Sant'Orsola-Malpighi General Hospital, Bologna, Italy (approval code: CHD2014). One author (AF) has full access to all the data in the study and takes responsibility for its integrity and the data analysis.
A blood sample was taken from all patients; informed signed consent had been obtained from all patients. Two SAFE TUBEs Ò (Geneticlab, Noventa Vicentina, Italy) were used to collect blood (10 ? 10 mL); these have liquid in which free DNA and RNA was preserved. The samples were then centrifuged at 3000 rpm for 10 min to obtain plasma. The plasma was centrifuged at 13000 rpm for 10 min and supernatant was then collected in a clean tube. A manual procedure was utilized to extract free RNA from 4 mL of maternal plasma, using a QIAvac 24 Plus vacuum manifold with QIAamp Ò Circulating NA kit (Qiagen) in accordance with the manufacturer's instructions. After this process, the extract was treated with DNaseI to digest free DNA. To obtain an optimal product, the free RNA extracted was purified using RNeasy Ò MinElute Ò Cleanup (Qiagen) and was then concentrated using Amicon Ò Ultra 0.5 mL centrifugal filters (Merck Millipore). Finally, the free RNA was quantified using QIAxpert Ò in accordance with the manufacturer's instructions.
NanoString technology was used to identify aberrantly expressed genes in second trimester pregnancies with CHDs (CNTRA and LVOT obstructions) as compared to controls. Customized probes corresponding to 135 genes were designed and manufactured by NanoString (the list is available as a supplementary file). Genes related to CHD were selected based on previous publications [21, 22] and were chosen for their known biological roles in cardiac and fetal development. This platform permits quantifying the expression of up to 800 targets, without the need to use enzymes, which could introduce bias. The nCounter Analysis System utilizes a novel digital color-coded barcode technology that is based on direct multiplexed measurement of gene expression and offers high levels of precision and sensitivity (\1 copy per cell). The technology uses a molecular ''barcodes'' and single molecule imaging to detect and count hundreds of unique transcripts in a single reaction.
Each color-coded barcode is attached to a single targetspecific probe corresponding to a gene of interest. Mixed together with controls, they form a multiplexed CodeSet. The data were collected by counting the individual barcodes using the nCounter TM Prep Station and the nCounter TM Digital analyser (nSolver Ò Analysis Software 2.6). First, the Reporter Library File (RLF) was loaded to provide nSolver TM software with CodeSet information, such as probe identification names and target mRNA sequences. Subsequently, the Reporter Code Count (RCC) files were also imported, which contain the raw counts of the probes for the individual analysed samples.
After converting to a readable format as a spreadsheet, raw data were exported to be normalized. An accurate background estimate is essential for interpreting expression data.
After standardization, a statistical analysis was performed using Welch's t test to highlight significant differences in the gene expression of selected transcripts.
The RNA expression of those genes selected according to the NanoString results was tested using the Real-Time TaqMan assay (Life Technologies Ò ). To investigate the integrity of the plasma RNA, the concentration of the GAPDH transcript was furthermore measured in the plasma using a Real-Time assay. Before the assay, 5 lg of total RNA was retro-transcripted using the GoScript TM Reverse Transcription System (Promega Ò ). The Real-Time assay was then carried out using the CFX96 Real-Time System (BIORAD Ò ) according to the following cycle: 10 min at 95°C, 50 cycles of 15 min at 95°C and 1 min at 60°C. Each cDNA sample was analysed in duplicate.
The polymerase chain reaction (PCR) signal of the target transcript was expressed as relative quantification using the 2 -DDCT method (where CT is the crossing threshold), which is a convenient way to analyse the relative changes in gene expression in an affected group of patients when compared with controls. Details regarding the methods have been reported by Livak and Schmittgen [24] The data were expressed as 2 -DDCT . Higher values of 2 -DDCT correspond to an increase in the expression of the gene in the affected sample as compared to the controls.
Statistics
Since this was a case-control study design, sample size analysis was carried out by calculating the power obtained for the available number of subjects. A bootstrap procedure was also carried out for all the analyses to verify the robustness of the results.
Univariate analysis was carried out using a t test after testing for a normal distribution of the variables of interest.
Linear discriminant analysis (LDA) was the multivariable tool used to combine all the mRNA species with discriminant ability for the two categories of CHDs (CNTRA and LVOT obstruction). A multivariable receiver operating characteristic (ROC) curve was finally generated in order to calculate the detection rate (DR) of mRNA species of interest at a false positive rate (FPR) of 5, 10 and 20%. LDA is indicated more than other multivariate techniques with binary outcome, such as logistic regression, in the presence of normally distributed variables and when all the variables are continuous. Again, logistic regression calculates the odds which must be adjusted for the incidence of the disease in order for it to be prospectively applicable. In this data set, instead, the number of affected cases (CHDs) does not reflect the real incidence of the defects at all, and therefore, an odds calculation, even if adjustable, should yield an over-or an underestimation of the real discriminatory ability of the exploratory variables. Our group therefore preferred to calculate only an a-dimensional generic score (D-score) to distinguish CHDs from the controls.
Results
From 1 Jan 2016 to 31 Dec 2016, 42 cases with CNTRA or LVOT obstruction were recruited for the purpose of the study in our Centre. For each case, a control of same gestational age (19-24 weeks) was also enrolled. For 6 cases, no complete follow-up was available, and they were therefore excluded from the analyses, which were carried out on the remaining 36 CHD cases and 42 controls. There were 20 cases of CNTRA and 16 cases of LVOT anomalies. All the neonates were born at our hospital and were examined by a paediatrician. Table 1 shows all the demographic characteristics of the series enrolled in the study and the values of 2 -DDCT mRNA species in both cases and controls. Table 2 presents the list of the specific CHD cases diagnosed at echocardiography and confirmed at delivery. The NanoString test allowed the identification of a pool of four genes having significantly altered gene expression and when the affected group was compared to the control group: mitogen-activated protein kinase 1 (MAPK1), IQ motif containing GTPase-activating protein 1 (IQGAP1), nicotinamide phosphoribosyltransferase (NAMPT or PBEF1 or Visfatin) and ADP ribosylation factor 1 (ARF1)
In the Real-Time PCR assay, the genes identified with NanoString and an extra gene expressed exclusively from the placenta, the chorionic somatomammotropin hormone 1 (CSH1) were analysed. This gene was used to determine the presence of free fetal RNA into the maternal plasma samples.
The housekeeping gene selected was GAPDH; it was the one that was most constant and least variable among all those tested in the control group and the affected group. Again, according to current knowledge, the GAPDH gene has not previously been linked to any CHD. For the future, it will be necessary to recruit another housekeeping gene to consolidate the results.
Univariable Analysis
These four genes with differential expressions were subsequently tested using Real-Time PCR. No difference in mRNA gene expression was observed with increasing gestational age, probably because of the tight window herein considered (19-24 weeks). Table 3 reports the values of the mRNAs in both cases and controls after conversion to a multiple of the mean of the controls. As shown, all the species considered in this study had a significant degree of aberrant expression. Levene's test for equality of variances yielded a p value \0.05 for all four genes.
Multivariable Analysis
LDA was carried out by adding only those mRNA species with a statistical difference, MAPK1, IQGAP1 and Visfatin. In the bootstrap analysis, ARF1 did not reach statistical significance and was therefore excluded from further analysis.
Before carrying out the LDA, the data set was converted into a multiple of the mean of the control group to reduce the data dispersion. Therefore, for each mRNA species, the control group always scored a mean value of 1.00 ± SD.
The variables of interest were tested for Gaussian distribution using the Shapiro-Wilk test. Table 3 reports the D-score quoted for cases and controls. Bootstrap analysis showed a Wilk's k associated with a discriminant function of 0.719 (p value \0.001). Again, by analysis of standardized canonical coefficients, it emerged that IQGAP1 had the highest discriminant value followed by MAPK1 and Visfatin. Figure 1 shows the probability-plot (P-plot) of the data stratified according to group. As shown, the controls presented a Gaussian pattern by visual inspection, at least between the 10th and 90th centiles of the unaffected, as judged by a P-plot.
The cases also showed a Gaussian pattern at the same centile interval, but there were six outliers which scored very aberrant D values. There were three CNTRA (2 cases of TGA and 1 case of TOF) and three LVOT obstruction cases [3 cases of coarctation of the aorta with VSD, aberrant right subclavian artery (ARSA) and hypoplastic aortic arch, respectively]. Table 4 reports the area under the curve (AUC) for each mRNA. As shown, only MAPK1 and IQGAP1 reached a significant p value in determining the AUC. However, even if Visfatin did not satisfy all the required criteria for statistical significance, it contributed to a slightly better performance of the discriminant function (as tested by a more significant Wilk's k, observed when it was added to the LDA) and was therefore added to the final discriminant model. Using the combination of these mRNAs, at a 5, 10 and 20% FPR, the ROC curve obtained using the D-score as an exploratory variable showed a DR for CHDs of 61.1, 61.1 and 66.7% at 5, 10 and 20% of FPR, respectively, with a power of 100% at a Type I error of 5% (Table 4 ; Fig. 2a) .
By splitting the data set for type of anomaly (CNTRA or LVOT obstruction), a slightly better performance was observed for LVOT obstruction as shown in Table 4 . The DRs were 60, 60 and 65% for CNTRA and 62.5, 62.5, 68.8% for LVOT obstruction, respectively, at 5, 10 and 20% FPR (Fig. 2b, c ) with a power of 99.9% at a Type I error of 5%.
Discussion
This study has demonstrated that NanoString technology is able to identify a panel of circulating mRNA species in maternal plasma and that the mRNA expression of aberrantly expressed genes in mothers carrying a fetus with CNTRA or LVOT obstruction is altered as compared to the controls.
Our group has previously shown that placental transcriptome in pregnancies affected by a range of CHDs differed from the placenta of healthy controls, and that these changes were also detectable in circulating mRNA in the maternal blood [21, 22] . Other studies have demonstrated that circulating miRNA also has a different distribution in maternal plasma and they have proposed that these nucleic acid species are suitable as a possible screening tool [23] . Again, a recent paper by Whitehead et al [25] reviewed the possible use of circulating acid in maternal species, including mRNAs, as a possible tool for screening some fetal diseases, such as CHDs.
Based on the results herein presented and obtained from a new population of CNTRA and LVOT obstruction cases, the mRNA species with significant degrees of aberrant expression were MAPK1, IQGAP1 and Visfatin, which reached a combined DR of 61.1% at 5% FPR.
All three genes have previously been widely associated with a cardiac morphology and function. The MAPK1 gene mapping on the 22q11.2 region, has an essential function in embryonic development and in the generation of extraembryonic ectoderm, from which the fetal side of the Fig. 1 P-plot of the discriminant values (D-score) in the CNTRA cases (cross sign), in the LVOT anomalies cases (plus sign) and in the controls (bullet). On the right side of the frame, the correspondent Gaussian distributions are also reported. When the points plotted for each category follow an approximate straight line, the distribution is, by definition, Gaussian [26] . The MAPK1 gene and the gene haploinsufficiency due to microdeletion (DiGeorge syndrome) have been consistently implicated in the etiopathogenesis of CHDs, including the CNTRA group. However, it is worth noting how, in 22q.11.2 microduplication, the same cardiac features have also been reported, including CNTRA [27] . Our group therefore believes that our results are very interesting since higher values of the mRNA for MAPK1 gene in CNTRA were found, allowing a speculation regarding the possible correlation between circulating mRNA transcripts and their corresponding genes. If confirmed, the result would open new frontiers in non-invasive prenatal diagnosis since it would allow a possible diagnosis of chromosomal deletion or duplication by using the mRNA in maternal plasma. Little is known regarding the IQGAP1 gene, but it has been demonstrated that this gene (expressed by many tissues including trophoblasts) codes for a scaffold protein, which is required to activate the extracellular signalregulated kinase 1/2 (ERK1/2), a system produced as a response to cardiac pressure overload. In particular, the ERK1/2 signalling is a key pathway in cardiomyocyte hypertrophy activated in response to many different stress stimuli [28] .
More interestingly, IQGAP1 and MAPK1 interact since the role of the scaffold protein of IQGAP1 is also necessary for the MAPK1 pathway [29] .
Visfatin (or NAMPT or PBEF1) is a gene invoking the hypertrophic response of cardiomyocytes [30] . Higher mRNA levels have been associated with a protective mechanism aimed at improving the cardiac function in patients affected with dilated cardiomyopathy and systolic heart failure [31] . Visfatin is also expressed in placental tissue, and it has been associated with amniotic fluid volume control by regulating amnion permeability in conjunction with the vascular endothelial growth factor (VEGF) [32] .
Both IQGAP1 and Visfatin are associated with congestive heart failure. Based on this, it can be concluded that AUC area under receiver operating characteristic curve, CHD congenital heart defect, LVOT left-ventricular outflow tract, CNTRA conotruncal anomalies, CI confidence interval the higher level of mRNA for IQGAP1 and Visfatin genes in maternal plasma can be explained by the presence of a fetal pressure overload typical of some CNTRA and LVOT obstruction. It is worth noting that previous results from our group [21] showed many aberrant mRNA expressions in the placental tissues of CHD infants for some genes involved in congestive heart failure and abnormal contractile activity.
Again, our previous study [22] showed that the CHDs from a pool that included seven different categories of CHD, including LVOT, CNTRA, valve defects, atrioventricular septal defects, abnormalities of the right or left heart and heart rhythm disorders), which scored the most aberrant D-scores belonged to the LVOT obstruction and CNTRA groups by using a panel of four mRNA species [22] . Therefore, to date, it seems that the most suitable CHDs for screening purposes are CNTRA and LVOT obstruction, especially if complicated with other features.
Fetal echocardiography is, at present, the main screening tool for CHDs. A systematic review was conducted to evaluate the accuracy of ultrasound examination in detecting fetal CHDs and it reported a DR of 85% [95% confidence interval (CI) 78-90%] and a specificity of 99% (95% CI 98-100%) [33] . However, fetal echocardiography is difficult to perform, operator-dependent and needs interdisciplinary collaboration. In clinical practice, it is only available in tertiary centres, usually reserved for referral patients. A routine anomaly scan, performed by sonographers or midwives in some countries, is often the only first-level screening tool for fetal CHDs and has consistently lower DRs. For example, data from American centres (northern California) have shown that the DR for the major forms of CHD ranged from 20 to 82% (average 28%) [34] .
Considering that fetal echocardiography is difficult to perform and is not always available, and that undetected CHDs are potentially life-threatening conditions, molecular screening for CHDs would have great clinical impact. This test could be performed with potentially very good results in cases with increased nuchal translucency and normal karyotype, that are known to be at high risk for fetal cardiac anomalies.
The present study has some limitations. In fact, even if we matched for gestational age, had an adequate sample size, carried out a bootstrap procedure, and used a small number of covariates in the multivariable analysis, it is still possible that some unknown confounding factors could affect our results. Moreover, the RNA preservation is a crucial point in the quality of the results, and the entire process of blood collection must be properly handled and monitored. In this study, a manual extraction technique was used based on silica columns for isolating circulating fetal RNA. The RNA was then purified and concentrated. In this way, the degradation was minimized, and the quality of the RNA was optimal and suitable for NanoString technology and Real-Time assay. The changes in mRNA abundance for the four genes examined are very small, i.e. 1.27 versus 1.0 for ARF1. These really are at the limits of the real-time PCR technology in use today. Finally, there are no data in the medical literature from other independent groups that will allow a comparison with our results.
However, our data confirmed our previous finding that an abnormal expression of some mRNA species in CHDs can be detected in maternal plasma in the second trimester of pregnancy, and that the aberration was associated with a discriminant ability for some specific group of CHDs, which is worth noting.
In conclusion, this study has demonstrated that molecular screening of CNTRA and LVOT obstruction in the second trimester of pregnancy with NanoString technology is potentially feasible. Additional studies are needed to improve the number of candidate genes and to verify whether these aberrations are detectable from the first trimester of pregnancy. Prospective studies are also needed to test the overall accuracy of these genes that should be 90-95% to be clinically useful and to calculate the relative predictive positive value in the general population.
